Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.32 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.32 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.32 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675887 | 0.93 | MAPT (0.38) | GPR84ALDH1A1TDP1ALPLMAPK1 | |
| SCHEMBL17229798 | 0.86 | TRPA1 (0.33) | GPR84MAPK1TRPA1 | |
| SCHEMBL18556914 | 0.84 | GPR84 (0.39) | GPR84ALDH1A1TDP1ALPLMAPK1 | |
| SCHEMBL25843809 | 0.81 | EIF4A3 (0.39) | — | |
| SCHEMBL25843813 | 0.78 | PRKAB2 (0.33) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL25691952 | 0.78 | PRKAB2 (0.32) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL5678104 | 0.77 | ADORA2A (0.47) | GPR84ALDH1A1TDP1ALPLMAPK1 | |
| SCHEMBL18556925 | 0.73 | GPR84 (0.42) | GPR84ALDH1A1TDP1ALPLMAPK1 | |
| SCHEMBL16675892 | 0.72 | GSK3B (0.44) | GPR84ALDH1A1TRPA1 | |
| SCHEMBL20462862 | 0.72 | MAPK1 (0.33) | GPR84MAPK1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920012-B2 | Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920012-B2 | Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150152063-A1 | INDAZOLE GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-06-04 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152063-A1 | INDAZOLE GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1D | GPR84 2503/4885ALDH1A1 1548/4885TDP1 701/4885 |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | GPR84 1893/4885ALDH1A1 2346/4885TDP1 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.